MA: received travel and accommodation expenses - Hairy Cell Leukemia Foundation; VB received consulting fees- Abbvie, AstraZeneca, BeiGene, Janssen, Merck, Lilly, honoraria- CTC Communications, Fusion MD, Oncology Education, funded grants or clinical trials- CIHR, LLSC, Lymphoma Canada, HCL Foundation, CLC.3, Lilly, AstraZeneca, Janssen, Abbvie, Gilead, patent on kinase inhibitors and methods of use ; JB: advisory board-Jannsen, Abbvie, Beigene, AstraZeneca, research support from Merck, Oncternal, Biomea; SAB: Advisory board- Pharmacyclics, AbbVie, Beigene and AstraZeneca, received research funding from AstraZeneca; FF: Honoraria- Abbvie, Janssen-cilag, Beigene, Astra-Zeneca, speakers bureau- Abbvie, Janssen-Cilag, Beigene, Astra-Zeneca, travel and accommodation- Abbvie, Janssen-Cilag, Beigene, consulting- BC platform, private clinical activity at Southampton General Hospital Solent Suite; MG: Consultant- Astra Zeneca, Pharmacyclics, Ascerta, Axio, Inc, research funding from Hairy Cell Leukemia Foundation for Patient Data Registry, travel expenses - Hairy Cell Leukemia Foundation, Scientific Board Chair - Hairy Cell Leukemia Foundation Scientific Board (no reimbursement), Deciphera Pharmaceuticals., Scientific Honorarium- University of Pittsburgh; SI: Advisory board, received speaker fees or conference support : AbbVie, Astra Zeneca, Beigene, BMS, Gilead, Janssen, Takeda; RK: Coinventor of the NIH patent for moxetumomab pasudotox, received research drug and/or research funding from AstraZeneca, Novartis, Pfizer, Genentech, and Teva; SAP: Research funding- provided to Mayo Clinic from Janssen, AstraZeneca, Merck, and Genentech, Honoraria - Pharmacyclics, Merck, AstraZeneca, Janssen, BeiGene, Genentech, MingSight Pharmaceuticals, Ascentage Pharma, Eli Lilly, Novalgen Limited, Kite Pharma, and AbbVie; JHP: received consulting fees from Affyimmune Therapeutics, Amgen, Autolus, Be Biopharma, Beigene, Bright Pharmaceutical Services, Inc., Caribou Biosciences, Curocell, Galapagos, In8Bio, Kite, Medpace, Minerva Biotechnologies, Pfizer, Servier, Sobi, and Takeda, received honoraria from OncLive, Physician Education Resource, and MJH Life Sciences, serves on scientific advisory board of Allogene Therapeutics, Artiva Biotherapeutics and Green Cross Biopharma, and received institutional research funding from Autolus, Genentech, Fate Therapeutics, InCyte, Servier, and Takeda; KR: Research funding (institution)-Genentech, AbbVie, and Novartis, consulting - Genentech, AbbVie, Pharmacyclics, AstraZeneca, Beigene, LOXO@Lilly, and Janssen; JFS: Advisory board, speakers’ bureau, research funding or expert testimony - AbbVie, Astra Zeneca, Beigene, BMS, Genor Bio, Gilead, Janssen, Roche. Consultant, expert testimony: TG Therapeutics; MST: Research funding-AbbVie, Orsenix, BioSight, Glycomiometics, Rafael Pharmaceuticals, Amgen, Advisory boards- AbbVie, Daiichi-Sankyo, Orsenix, KAHR Oncolyze, Jazz Parmaceuticals, BioSight, Innate Pharmaceuticals, Kura, Syros Pharmaceuticals, Ipsen Biopharmaceuticals, Royalties- UpToDate, Committees-Foghorn Therapeutics (Adjudication Committee), HOVON HO156 (DSMB), American Society of Hematology Executive Committee (2018-2021); CST: Honorarium from Janssen, AbbVie, Lilly, Beigene and Merck, research funding from Janssen, AbbVie and Beigene; ET: Advisory board for Innate Pharma, Kite/Gilead and Deciphera Pharmaceuticals, research funding from Roche, holder of a patent on the use of mutant BRAF as HCL biomarker; XT: Consultant for Abbvie, Lipomed, Beigene, fees from Deciphera; TZ: Advisory role- Roche, Gilead, Beigene, Lilly, Janssen, AstraZeneca, Abbvie, Incyte, Novartis; PLZ: Advisory board or Spekers bureau- Secur Bio, Celltrio, Gilead, Janssen-Cilag, BMS, Servier, Sandoz, MSD, Astra Zeneca, Takeda, Roche, Eusapharma, Kyowa Kirin, Novartis, ADC Therap., Incyte, Beigene. The other authors declare no competing interests.